Wednesday, June 15th, 2016 - RnR Market Research

Respiratory Syncytial Virus (RSV) Infections Pipeline Market Companies Involved in Therapeutics Development are Ablynx NV,ADMA Biologics, Inc.,Agilvax, Inc.,Aridis Pharmaceuticals LLC,Artificial Cell Technologies, Inc.,AstraZeneca Plc,Aviragen Therapeutics, Inc.,Bavarian Nordic A/S,Celltrion, Inc.,Codagenix, Inc.,CureVac GmbH,DBV Technologies S.A.,Emergent BioSolutions Inc.,Enanta Pharmaceuticals, Inc.,Evec, Inc.,F. Hoffmann-La Roche Ltd.,GenVec, Inc.,Gilead Sciences, Inc.,GlaxoSmithKline Plc,Globavir Biosciences, Inc.,Humabs BioMed SA,iBio, Inc.,ILiAD Biotechnologies, LLC,Ilyang Pharmaceutical Co., Ltd,Immunovaccine, Inc.,Inovio Pharmaceuticals, Inc.,Johnson & Johnson,Kineta, Inc.,mAbxience S.A.,MedImmune, LLC,Medivir AB,Merck & Co., Inc.,Mucosis B.V.,NanoBio Corporation,Navigen Pharmaceuticals, Inc.,Novavax, Inc.,Panacea Biotec Limited,Profectus BioSciences, Inc.,Pulmocide Ltd,Regeneron Pharmaceuticals, Inc.,Romark Laboratories, L.C.,Sirnaomics, Inc.,Spider Biotech,Spring Bank Pharmaceuticals, Inc.,Takeda Pharmaceutical Company Limited,TechnoVax, Inc.,The International Biotechnology Center (IBC) Generium,Trellis Bioscience, Inc.,Vault Pharma Inc.,Vaxart, Inc.,VaxInnate Corporation,VBI Vaccines Inc.,Virometix AG,Visterra, Inc.,VLP Biotech, Inc.

The report provides comprehensive information on the therapeutics under development for Respiratory Syncytial Virus (RSV) Infections, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Respiratory Syncytial Virus (RSV) Infections and features dormant and discontinued projects.

Get 15% discount on this research report at

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.


  • The report provides a snapshot of the global therapeutic landscape of Respiratory Syncytial Virus (RSV) InfectionsThe report reviews pipeline therapeutics for Respiratory Syncytial Virus (RSV) Infections by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Respiratory Syncytial Virus (RSV) Infections therapeutics and enlists all their major and minor projectsThe report assesses Respiratory Syncytial Virus (RSV) Infections therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Respiratory Syncytial Virus (RSV) Infections

Complete research report of 251 pages with TOC is available at

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Respiratory Syncytial Virus (RSV) Infections
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Respiratory Syncytial Virus (RSV) Infections pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

File Library

Contact Profile

RnR Market Research

About Us: is your single source for all market research needs. Our database includes 500,000+ market research reports from over 100+ leading global publishers & in-depth market research studies of over 5000 micro markets. With comprehensive information about the publishers and the industries for which they publish market research reports, we help you in your purchase decision by mapping your information needs with our huge collection of reports.

Connect with Us: 

G+ / Google Plus:



RSS / Feeds:

Ritesh Tiwari
P: + 1 888 391 5441


Respiratory Syncytial Virus (RSV) Infections Therapeutic Products under Development, Key Players in Respiratory Syncytial Virus (RSV) Infections Therapeutics, Respiratory Syncytial Virus (RSV) Infections Pipeline Overview, Respiratory Syncytial Virus (RSV




More Formats